靶向CD30嵌合抗原受体T细胞治疗复发难治性霍奇金淋巴瘤的临床治疗探讨

Clinical treatment of autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin's lymphoma

目的:探讨靶向CD30的嵌合抗原受体T细胞(CART-30)治疗复发难治性霍奇金淋巴瘤的安全性及有效性,建立相对成熟的治疗体系。方法:2014-2015年在我院对18例复发难治性霍奇金淋巴瘤患者进行CART-30细胞输注治疗,并随访观察。结果:18例患者均顺利接受细胞回输并完成随访,耐受性好,仅有2例患者出现≥3级毒副反应。7例患者疗效评估为部分缓解,6例为疾病稳定,客观反应率为39%(7/18),疾病控制率为72%(13/18),无疾病进展时间平均为9.5个月。结论:CART-30细胞治疗的安全性与有效性结合相对成熟的治疗体系,将使其成为复发难治性霍奇金淋巴瘤的一个新型治疗途径。

Objective：To study the safety and efficacy of CD30-targeting CART（CART-30）cells in patients with progressive relapsed or refractory Hodgkin＇s lymphoma,and establish a sophisticated treatment protocol.Method：A total of 18 progressive relapsed or refractory Hodgkin＇s lymphoma patients,who were treated with CART-30 cell infusion and followed up between 2014 and 2015in our hospital,were enrolled.Result：CART-30 cell infusion was tolerated,with grade ≥3toxicities occurring only in 2of 18 patients.Of the 18 evaluable patients,7cases achieved partial remission,and 6cases had stable disease after the infusion of CART-30 cells.The objective response was 39%,disease control rate was 72%,and the average progression free survival was 9.5months.Conclusion：CART-30 cell therapy is safe,feasible and efficient,and it provides a novel therapeutic strategy for relapsed or refractory Hodgkin＇s lymphoma.